Structure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy Recommendation
BMO Capital analyst Evan Seigerman has reiterated their bullish stance on GPCR stock, giving a Buy rating on November 5. Evan Seigerman has ...
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
NBC Los Angeles3d
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
BioSpace3d
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
AbbVie shares tumble after schizophrenia drug disappoints
US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms ...